Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) rose 15.3% on Thursday . The stock traded as high as $2.50 and last traded at $2.41. Approximately 3,883,331 shares traded hands during mid-day trading, an increase of 2,729% from the average daily volume of 137,279 shares. The stock had previously closed at $2.09.
Analysts Set New Price Targets
Separately, HC Wainwright restated a "buy" rating and issued a $7.00 price objective on shares of Immix Biopharma in a research report on Monday, February 10th.
Check Out Our Latest Research Report on Immix Biopharma
Immix Biopharma Stock Performance
The stock's 50 day simple moving average is $1.83 and its 200 day simple moving average is $1.92. The firm has a market cap of $54.36 million, a PE ratio of -2.29 and a beta of 0.27.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last issued its earnings results on Monday, March 24th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.09. As a group, analysts anticipate that Immix Biopharma, Inc. will post -0.87 earnings per share for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Immix Biopharma stock. SBI Securities Co. Ltd. bought a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 17,500 shares of the company's stock, valued at approximately $38,000. SBI Securities Co. Ltd. owned 0.06% of Immix Biopharma as of its most recent filing with the Securities and Exchange Commission. 11.26% of the stock is owned by hedge funds and other institutional investors.
About Immix Biopharma
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Featured Stories
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
